## **Trustees’ Annual Report for the period** ## **From 25/7/2020 Period start date To 24/7/2021 Period end date** **Charity name:** ASSOCIATION FOR THE GLOBAL ADVANCEMENT OF ENT SURGERY AND HEAD AND NECK CANCER RESEARCH ## **Charity registration number:** 1165453 ## **Objectives and Activities** ||SORP reference|| |---|---|---| |Summary of the purposes of
the charity as set out in its
governing document|Para 1.17|The advancement of health and relief of
sickness in the field of ear, nose and
throat/head and neck surgery and head
and neck disorders across the world in
particular but not exclusively by:
· Supporting the provision of awareness
and screening programmes
· Supporting cancer research by the
provision of grants
(AGA-ENT Charity Governing document -
version 1.1-21/1/2016)| |Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.|Para 1.17 and
1.19|· Supporting the provision of awareness
and screening programmes
· Supporting cancer research by the
provision of grants| |Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit|Para 1.18|Yes, the trustees have had regard.| ## **Additional information (optional)** ## You may choose to include further statements where relevant about: SORP reference N/A Para 1.38 Policy on grant making N/A Para 1.38 Policy on social investment including program related investment |Contribution made by
volunteers|Para 1.38|Minor contributions, e.g. help with website.| |---|---|---| |Other||N/A| ## **Achievements and Performance** ||SORP reference|| |---|---|---| |Summary of the main
achievements of the charity,
identifying the difference the
charity’s work has made to
the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.|Para 1.20|Our work has unfortunately been affected
by the pandemic, but we have aimed to
continue the fundraising in order to get the
programme established fully in 2022/2023
again
After our BICRAA app (www.bicraa.org)
had been successfully tested in India
(n=1049), showing that around 30% chew
betel nut (we would like to thank Prof.
Kelkar and Dr. Pethe from the Deenanath
Mangeshkar Hospital, Pune, for their
invaluable support), the app has continued
to help raise the awareness of the risks of
betel nut chewing.
We have continued working on a global
study to extend these efforts in India and
other countries.
With regard to our work in Indonesia, we
have continued to closely work with our
partners at the Dr. Sardjito Hospital/Gadjah
Mada University in Yogyakarta, Indonesia,
and affiliated district general hospitals in
collaboration with Prof. Bing Tan to support
the local Nasopharyngeal Cancer (NPC)
awareness and early detection programme
and to support research and publications of
results. The Storz company has continued
to support our programme and in 2019 we
were able to award four fellowship grants to
young surgeons, sponsored by a donation
by Storz, allowing them travel to low and
middle income countries and to helpi with
the local charitable work. In 2020 we
awarded two more fellowships and these
have unfortunately been delayed by the
pandemic, but will be completed in
2022/2023.| |**Additional information (optional)**
You may choose to include further statements|**Additional information (optional)**
You may choose to include further statements|where relevant about:| |---|---|---| ||Para 1.41|As above. Taking the above work into
account AGA-ENT has made contributions
to the advancement of health and relief of| |Achievements against
objectives set||sickness in the field of ear, nose and
throat/head and neck surgery and head
and neck disorders in low and middle
income countries. However, our work has
unfortunately been affected by the
pandemic, but we have aimed to continue
the fundraising in order to get the
programme established fully in 2022/2023
again.| |---|---|---| |Performance of fundraising
activities against objectives
set|Para 1.41|Good progress. Substantive funding will be
sought once the preliminary data are
published.| |Investment performance
against objectives|Para 1.41|N/A| |Other||N/A| ## **Financial Review** |**Financial Review**||| |---|---|---| |Review of the charity’s
financial position at the end
of the period|Para 1.21|24/7/2021| |Statement explaining the
policy for holding reserves
stating why they are held|Para 1.22|Year on year the charity hopes to increase
the reserves to be in line with 2 years
possible commitments| |Amount of reserves held|Para 1.22|£1000| |Reasons for holding zero
reserves|Para 1.22|N/A| |Details of fund materially in
deficit|Para 1.24|N/A| |Explanation of any
uncertainties about the
charity continuing as a going
concern|Para 1.23|N/A| **Additional information (optional)** You may choose to include further statements where relevant about: |The charity’s principal
sources of funds (including
any fundraising)|Para 1.47|Donations by private donors and donated
equipment.| |---|---|---| |Investment policy and
objectives including any
social investment policy
adopted|Para 1.46|N/A| |A description of the principal
risks facing the charity|Para 1.46|At present funds are sufficient to achieve
the aims set, but more funding needs to be
sought to continue to expand our work.
Ensuring the ongoing income is the most
important risk we manage.| |Other||N/A| ## **Structure, Governance and Management** |Description of charity’s
trusts:||| |---|---|---| |Type of governing document
(trust deed, royal charter)|Para 1.25|Constitution of the Association for the
Global Advancement of ENT Surgery and
Head and Neck Cancer Research (AGA-
ENT), a Charitable Incorporated
Organisation with voting members other
than its charity trustees
Date of constitution (last amended):
21/01/2016 (AGA-ENT Charity Governing
document - version 1.1 - 21/1/2016)| |How is the charity
constituted?
(e.g unincorporated
association, CIO)|Para 1.25|Charitable Incorporated Organisation| |Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees|Para 1.25|The current trustees volunteered to take on
these roles with the support of all founding
members and fulfil these roles in line with
the duties outlined in the AGA-ENT Charity
Governing document - version 1.1 -
21/1/2016| ## **Additional information (optional)** You may choose to include further statements where relevant about: |Policies and procedures
adopted for the induction
and training of trustees|Para 1.51|All duties outlined in the AGA-ENT Charity
Governing document - version 1.1 -
21/1/2016 and discussed during regular
Trustees’ meetings.| |---|---|---| |The charity’s organisational
structure and any wider
network with which the
charity works|Para 1.51|Charitable Incorporated Organisation with
voting members other than its charity
trustees| |Relationship with any
related parties|Para 1.51|Collaborators and partners globally who
help to achieve the outlined objectives,
usually within the network of Founding
Members.| |Other||N/A| ## **Reference and Administrative details** Charity name Association for the Global Advancement of ENT Surgery and - Head and Neck Cancer Research (AGA ENT) Other name the charity uses AGA-ENT Registered charity number 1165453 Charity’s principal address Association for the Global Advancement of ENT Surgery and Head and Neck Cancer Research (AGA-ENT), Beacon House, 113 Kingsway, London, WC2B 6PP ## **Names of the charity trustees who manage the charity** |1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**
**year **|**Name of person (or body) entitled**
**to appoint trustee (ifany)**| |---|---|---|---|---| ||Paul O’Flynn||5/2/2016 – current date|Membershipbody| ||Matt Lechner||5/2/2016 – current date|Membershipbody| ||Valerie J. Lund||5/2/2016 – current date|Membershipbody| ||Francis M. Vaz||5/2/2016 – current date|Membershipbody| ||Tim Tang||5/2/2016 - 4/6/2017|Membershipbody| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| |||||| ## – Corporate trustees names of the directors at the date the report was approved **Director name** N/A Name of trustees holding title to property belonging to the charity |**Trustee name**|**Dates acted if not for whole year**|| |---|---|---| |N/A||| |||| |||| |||| |||| |||| ## **Funds held as custodian trustees on behalf of others** Description of the assets None held in this capacity Name and objects of the N/A charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for N/A safe custody and segregation of such assets from the charity’s own assets ## **Additional information (optional)** ## **Names and addresses of advisers (Optional information)** |**Names and addresses of advisers (Optional information)**|**Names and addresses of advisers (Optional information)**|**Names and addresses of advisers (Optional information)**| |---|---|---| |**Type of**
**adviser**
**Name**
**Address**||| |N/A||| |||| |||| |||| |**Name of chief executive or names of senior staff members (Optional information)**||| |N/A||| ## **Exemptions from disclosure** Reason for non-disclosure of key personnel details The charity is too small still to employ personnel ## **Other optional information** N/A ## **Declarations** **The trustees declare that they have approved the trustees’ report above.** **Signed on behalf of the charity’s trustees** |**Signature(s)**
**Full name(s)**
**Position (eg Secretary,**
**Chair, etc)**
**Date**||| |---|---|---| ||Matt Lechner|Valerie J. Lund| ||
Trustee|| ||19/05/2022|| ||19/05/2022|| Receipts and payments accounts CC16a For the per￿$ To Section A Receipts and payments Unrestricted funds Endowment funds Total funds La51 ￿ar tothemtaregt£ A1 Recei rk>nAtion5 Fd10￿1p Fundir*J 8.500 3,192 3.192 Sub total(Gmss for 12.600 AR) A2 Asset aEKI investment sales. see table . tot 6.792 6,792 12,500 A3Pa ents Fwdtsising costs Web h05ts Fe1bw￿ljP ￿rdS Research costs 121 121 421 634 4,000 5,000 PDDtiry. ￿stage and stabonory ce costs 132 960 Sundry exp8fLses 137 BÈnk charges 41 Sub total 11.584 A4 Asset and fin￿lment urchase5 s& table Sub total TotaIpa￿nents 11,584 Net of r8ceiptsl(paTrrynents) AS Transters l*lwetn funds Cash funds last year end Cash funds Ihis year end 916 4.128 10,576 4,128 10,576 3,212 4,120 Section B Statement of assets and liabilities at the end of the period UnTestricted funds Restricted funds Endowwnent funds to neares1£ to nea￿&t É 81 Cash funds 10.576 Tolal ca4R fun¢ts 10,576 xxwd(s)} Unrestrthd fund5 to I*¥￿st £ Endowment funds funds to nearest £ Delails to neaies¢£ Current value l¢Jptional Detalls ¥s#et t C05t (op￿onall B3 Investment assets FI￿d to *thich Gurrent value ional Detalls Cost lotthn￿l B4 Assets retained forlhe harity's use F￿￿1*o￿￿1ch "at*"lity rel*s w￿￿￿ loptK*nall Details BS Liabilities Siyned by one or truBtees on beham of all the tru5tee5 Sigmature Pn"nt Name- Date of roval Ni. M4rr LiCHfvJt 2¥16/2&1